Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA

International Journal of Emergency Medicine

Devina Singh¹  Ranjit Banwait¹  Dipendra Parajuli²  Lexie Finer³  Hale Toklu⁴  Vaibhav Rastogi⁵  Latha Ganti⁶ 

[1] Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando, Florida, USA;Department of Gastroenterology, University of Louisville, Louisville, Kentucky, USA;HCA Healthcare Graduate Medical Education, Nashville, Tennessee, USA;HCA Healthcare Graduate Medical Education, Nashville, Tennessee, USA;Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando, Florida, USA;HCA Healthcare Graduate Medical Education, Nashville, Tennessee, USA;Envision Physician Services, Plantation, Florida, USA;HCA Healthcare Graduate Medical Education, Nashville, Tennessee, USA;Envision Physician Services, Plantation, Florida, USA;Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando, Florida, USA;

关键词: Liver;    Pancreas;    Mortality;    SARS-CoV2;   

DOI  :  10.1186/s12245-021-00393-2

来源: Springer

【 摘 要 】

Background(1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. (2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity, and length of stay in this cohort.ResultsForty-five thousand three hundred sixty patients were included in the analysis, 62.82% of which had either hepatic or pancreatic injury. There was a significant upward trend in transaminases, alkaline phosphatase, prothrombin time, bilirubin, lactate dehydrogenase, and lipase and a downward trend in albumin with an increase in disease severity. COVID-19-positive patients with hepato-pancreatic injury have a significantly higher mortality (OR 3.39, 95%CI 3.15–3.65) after controlling for the differences in age, sex, race/ethnicity, liver cirrhosis, and medication exposures. They also have increased disease severity (OR 2.7, 95%CI 2.5–2.9 critical vs mild/moderate; OR 1.4, 95% CI 1.3–1.5 severe vs mild/moderate) and longer hospital length of stay (2 days).ConclusionCOVID-19 can cause liver injury. Mortality, disease severity, and hospital length of stay are increased in COVID-19 patients with hepatopancreatic injury.Graphical Abstract

【 授权许可】

CC BY